ESHAP is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory lymphomas and Hodgkin's lymphoma. In combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R.[1]
R-ESHAP consists of:
Rituximab, an anti-CD20-directed monoclonal antibody that kills both normal and malignant B-lymphocytes
Etoposide, an epipodophyllotoxin topoisomerase inhibitor
Solu-Medrol - Methylprednisolone, which is a glucocorticoid that can lyse lymphocytes
High-dose Ara-C - cytarabine
Platinol - Cisplatin, a platinum-based antineoplastic agent, also an alkylating antineoplastic agent.
^ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.
combination with monoclonal antibody Rituximab it is called R-ESHAP or ESHAP-R. R-ESHAP consists of: Rituximab, an anti-CD20-directed monoclonal antibody...
Global Information